Accellix Platform Chosen by the American Red Cross for Rapid and Accurate Allogeneic Source Material Characterization for Cell Therapy Development

Contributed by: Business Wire

Logo

Tags

Science

Other Science

Biotechnology

Research

Pharmaceutical

Oncology

Health

Genetics

assay cytometry point-of-need blood donor characterization leukopak lymphocyte

More Like This

Accellix Appoints Dr. Félix A. Montero-Julian as Vice President of Scientific Affairs

PR Newswire associated0

A Decade of Cell & Gene Therapy Manufacturing and Major GMP Facility Expansion: Cellex's Track Record of Scalable Excellence

PR Newswire associated0

Gift of Life Biologics and Cellex Cell Professionals GmbH Celebrate Successful Partnership to Deliver High-Quality Starting Materials for Final Drug Product Manufacturing in Cell and Gene Therapy

PR Newswire associated0

AvenCell Announces First Patient Dosed in a Phase IA Study with lead product candidate AVC-201, a Novel Allogeneic CD123-Directed Switchable CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia and other CD123 Hematological Malignancies

Ori Biotech and Charles River Laboratories Collaborate to Accelerate Life-Saving Cell and Gene Therapy Development and Manufacturing

PR Newswire associated0

Cellply launches its end-to-end single cell potency characterization platform VivaCyte

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial

PR Newswire associated0

The American National Red Cross Teams Up With Velico Medical In The Blood Center Education Program